Jacob George
Corporate Officer/Principal at The Hebrew University of Jerusalem
Jacob George active positions
| Companies | Position | Start | End |
|---|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - | - |
Career history of Jacob George
Former positions of Jacob George
| Companies | Position | Start | End |
|---|---|---|---|
Chemomab Ltd.
 Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Director/Board Member | 01/01/2011 | - |
| Founder | 01/01/2011 | - | |
| NOTABLE LABS, LTD. | Chief Tech/Sci/R&D Officer | 27/01/2000 | - |
| Founder | 27/01/2000 | - |
Training of Jacob George
| Technion-Israel Institute of Technology | Doctorate Degree |
Statistics
International
| Israel | 5 |
Operational
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Health Technology |
- Stock Market
- Insiders
- Jacob George
- Experience
